{"success":true,"data":{"pressRelease":{"id":"72034","rtpr_id":"nBw35lTBPa","ticker":"CDIO","exchange":"NASDAQ","all_tickers":["CDIO"],"title":"Atlas Healthcare Physicians to Cover Cardio Diagnostics’ Precision Cardiovascular Medicine Tests Across Its Network","author":"Business Wire","published_at":"2026-06-24T12:35:00.102Z","article_body":"Atlas Healthcare Physicians to Cover Cardio Diagnostics’ Precision\nCardiovascular Medicine Tests Across Its Network\n\nCardio Diagnostics Holdings, Inc.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fcdio.ai%2F&esheet=54559164&newsitemid=20260624992562&lan=en-US&anchor=Cardio+Diagnostics+Holdings%2C+Inc.&index=1&md5=41e7d6be8d7cf84774bf2c3a578c9153)\n(Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company,\nannounced that Atlas Healthcare Physicians (AHP)\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ahpscipa.com%2Findex.php&esheet=54559164&newsitemid=20260624992562&lan=en-US&anchor=Atlas+Healthcare+Physicians+%28AHP%29&index=2&md5=48e4385552d03fff9ec889b866276f46)\n, a community-driven, independent physician association (IPA) based in\nSouthern California, will cover Cardio Diagnostics’ tests, Epi+Gen CHD™\nand PrecisionCHD™, for their members with prior authorization beginning May\n2026. AHP consists of an expansive network of primary care and specialists,\nhospitals, and ancillary providers serving managed care populations across Los\nAngeles and Orange County.\n\nProviders will recommend Epi+Gen CHD™ or PrecisionCHD™ based on a\npatient’s medical history. Epi+Gen CHD™ assesses the three-year risk of a\ncoronary heart disease (CHD) event, including a heart attack. PrecisionCHD™\naids in diagnosing CHD and provides the specific molecular drivers of CHD for\neach patient to help inform more personalized care.\n\nEpi+Gen CHD™ and PrecisionCHD™ are simple, physician-ordered blood tests\nthat do not require exposure to radiation or fasting. As a result, they\nseamlessly integrate into clinical workflows and do not require specialized\ninfrastructure to administer.\n\n“At Atlas Healthcare Physicians, we are committed to providing our\nphysicians with innovative tools that support earlier detection, personalized\ntreatment planning, and improved patient outcome,” said Tam Doan, MBA, Chief\nOperating Officer of Atlas Healthcare Physicians. “Our collaboration with\nCardio Diagnostics reflects our shared commitment to expanding access to\nadvanced cardiovascular diagnostics, empowering providers to make more\ninformed clinical decisions, and helping patients better manager their heart\nhealth.”\n\n“IPAs are uniquely positioned to drive better cardiovascular outcomes across\ntheir member populations and the right precision medicine tools can make a\nmeaningful difference,” remarked Meesha Dogan, PhD, CEO and Co-Founder of\nCardio Diagnostics. “By covering Epi+Gen CHD™ and PrecisionCHD™, AHP is\ngiving its providers the ability to identify risk earlier, tailor care to each\npatient’s unique cardiovascular profile, and avoid costly downstream\ninterventions that come from delayed or missed diagnoses. That’s a win for\npatients, for providers, and for the network.”\n\nAccording to the California Department of Public Health, cardiovascular\ndisease is a leading cause of death in California\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.cdph.ca.gov%2FPrograms%2FCCDPHP%2FDCDIC%2FCDCB%2FCDPH%2520Document%2520Library%2FCVDBurdenReport2016_ADA.pdf&esheet=54559164&newsitemid=20260624992562&lan=en-US&anchor=cardiovascular+disease+is+a+leading+cause+of+death+in+California&index=3&md5=cb606c27c0e9c4167e87941ce44a5f12)\n— and the largest economic burden on the state. While cardiovascular care\nplaces a significant cost challenge at both a state and national level, the\ncost of delaying action until symptoms manifest is far greater. This\npartnership reflects Cardio Diagnostics’ continued expansion of access to\nprecision cardiovascular medicine across the United States.\n\nAbout Atlas Healthcare Physicians\n\nAHP is an IPA dedicated to improving the health and well-being of communities\nthroughout Southern California. AHP partners with primary care and\nspecialists, hospitals, and ancillary providers to deliver coordinated,\nhigh-quality healthcare to managed care populations across Los Angeles and\nOrange County. Through a commitment to provider support, operational\nexcellence, and innovative healthcare solutions, AHP empowers its network to\ndeliver accessible, patient-centered care while advancing quality outcomes and\nvalue-based healthcare initiatives.\n\nAbout Cardio Diagnostics\n\nCardio Diagnostics is an artificial intelligence-powered precision\ncardiovascular medicine company that makes cardiovascular disease prevention,\ndetection, and management more accessible, personalized, and precise. The\nCompany was formed to further develop and commercialize clinical tests by\nleveraging a proprietary Artificial Intelligence (AI)-driven Integrated\nGenetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease\nto become one of the leading medical technology companies for improving\nprevention, detection, and treatment of cardiovascular disease. For more\ninformation, please visit https://cdio.ai/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fcdio.ai%2F&esheet=54559164&newsitemid=20260624992562&lan=en-US&anchor=https%3A%2F%2Fcdio.ai%2F&index=4&md5=a537a221c1f6b903ed43cf8fc24f8c1b)\n\nForward-Looking Statements\n\nCertain statements and information included in this press release constitute\n“forward-looking statements” within the meaning of the Private Securities\nLitigation Act of 1995. When used in this press release, the words or phrases\n“will”, “will likely result,” “expected to,” “will continue,”\n“anticipated,” “estimate,” “projected,” “intend,” “goal,”\nor similar expressions are intended to identify “forward-looking\nstatements” within the meaning of the Private Securities Litigation Reform\nAct of 1995. Such statements are subject to certain risks, known and unknown,\nand uncertainties, many of which are beyond the control of the Company. Such\nuncertainties and risks include but are not limited to, our ability to\nsuccessfully execute our growth strategy, changes in laws or regulations,\neconomic conditions, dependence on results are discussed in the Current Report\non Form 10-K for the period ended in December 31, 2025, under the heading\n“Risk Factors” in Part I, Item IA thereof, and other documents filed from\ntime to time with the Securities and Exchange Commission. Such factors could\nmaterially adversely affect the Company’s financial performance and could\ncause the Company’s actual results for future periods to differ materially\nfrom any opinions or statements expressed within this press release.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260624992562/en/\n(https://www.businesswire.com/news/home/20260624992562/en/)\n\nInvestors \n\nInvestor Relations\n\n855-226-9991\n\ninvestors@cdio.ai (mailto:investors@cdio.ai)\n\nMedia & Public Relations \n\nPublic Relations\n\n855-226-9991\n\npr@cdio.ai (mailto:pr@cdio.ai)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw35lTBPa","title":"Atlas Healthcare Physicians to Cover Cardio Diagnostics’ Precision Cardiovascular Medicine Tests Across Its Network","author":"Business Wire","ticker":"CDIO","created":"2026-06-24T12:35:00.102Z","tickers":["CDIO"],"exchange":"NASDAQ","article_body":"Atlas Healthcare Physicians to Cover Cardio Diagnostics’ Precision\nCardiovascular Medicine Tests Across Its Network\n\nCardio Diagnostics Holdings, Inc.\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fcdio.ai%2F&esheet=54559164&newsitemid=20260624992562&lan=en-US&anchor=Cardio+Diagnostics+Holdings%2C+Inc.&index=1&md5=41e7d6be8d7cf84774bf2c3a578c9153)\n(Nasdaq: CDIO), an AI-powered precision cardiovascular medicine company,\nannounced that Atlas Healthcare Physicians (AHP)\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.ahpscipa.com%2Findex.php&esheet=54559164&newsitemid=20260624992562&lan=en-US&anchor=Atlas+Healthcare+Physicians+%28AHP%29&index=2&md5=48e4385552d03fff9ec889b866276f46)\n, a community-driven, independent physician association (IPA) based in\nSouthern California, will cover Cardio Diagnostics’ tests, Epi+Gen CHD™\nand PrecisionCHD™, for their members with prior authorization beginning May\n2026. AHP consists of an expansive network of primary care and specialists,\nhospitals, and ancillary providers serving managed care populations across Los\nAngeles and Orange County.\n\nProviders will recommend Epi+Gen CHD™ or PrecisionCHD™ based on a\npatient’s medical history. Epi+Gen CHD™ assesses the three-year risk of a\ncoronary heart disease (CHD) event, including a heart attack. PrecisionCHD™\naids in diagnosing CHD and provides the specific molecular drivers of CHD for\neach patient to help inform more personalized care.\n\nEpi+Gen CHD™ and PrecisionCHD™ are simple, physician-ordered blood tests\nthat do not require exposure to radiation or fasting. As a result, they\nseamlessly integrate into clinical workflows and do not require specialized\ninfrastructure to administer.\n\n“At Atlas Healthcare Physicians, we are committed to providing our\nphysicians with innovative tools that support earlier detection, personalized\ntreatment planning, and improved patient outcome,” said Tam Doan, MBA, Chief\nOperating Officer of Atlas Healthcare Physicians. “Our collaboration with\nCardio Diagnostics reflects our shared commitment to expanding access to\nadvanced cardiovascular diagnostics, empowering providers to make more\ninformed clinical decisions, and helping patients better manager their heart\nhealth.”\n\n“IPAs are uniquely positioned to drive better cardiovascular outcomes across\ntheir member populations and the right precision medicine tools can make a\nmeaningful difference,” remarked Meesha Dogan, PhD, CEO and Co-Founder of\nCardio Diagnostics. “By covering Epi+Gen CHD™ and PrecisionCHD™, AHP is\ngiving its providers the ability to identify risk earlier, tailor care to each\npatient’s unique cardiovascular profile, and avoid costly downstream\ninterventions that come from delayed or missed diagnoses. That’s a win for\npatients, for providers, and for the network.”\n\nAccording to the California Department of Public Health, cardiovascular\ndisease is a leading cause of death in California\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.cdph.ca.gov%2FPrograms%2FCCDPHP%2FDCDIC%2FCDCB%2FCDPH%2520Document%2520Library%2FCVDBurdenReport2016_ADA.pdf&esheet=54559164&newsitemid=20260624992562&lan=en-US&anchor=cardiovascular+disease+is+a+leading+cause+of+death+in+California&index=3&md5=cb606c27c0e9c4167e87941ce44a5f12)\n— and the largest economic burden on the state. While cardiovascular care\nplaces a significant cost challenge at both a state and national level, the\ncost of delaying action until symptoms manifest is far greater. This\npartnership reflects Cardio Diagnostics’ continued expansion of access to\nprecision cardiovascular medicine across the United States.\n\nAbout Atlas Healthcare Physicians\n\nAHP is an IPA dedicated to improving the health and well-being of communities\nthroughout Southern California. AHP partners with primary care and\nspecialists, hospitals, and ancillary providers to deliver coordinated,\nhigh-quality healthcare to managed care populations across Los Angeles and\nOrange County. Through a commitment to provider support, operational\nexcellence, and innovative healthcare solutions, AHP empowers its network to\ndeliver accessible, patient-centered care while advancing quality outcomes and\nvalue-based healthcare initiatives.\n\nAbout Cardio Diagnostics\n\nCardio Diagnostics is an artificial intelligence-powered precision\ncardiovascular medicine company that makes cardiovascular disease prevention,\ndetection, and management more accessible, personalized, and precise. The\nCompany was formed to further develop and commercialize clinical tests by\nleveraging a proprietary Artificial Intelligence (AI)-driven Integrated\nGenetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease\nto become one of the leading medical technology companies for improving\nprevention, detection, and treatment of cardiovascular disease. For more\ninformation, please visit https://cdio.ai/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fcdio.ai%2F&esheet=54559164&newsitemid=20260624992562&lan=en-US&anchor=https%3A%2F%2Fcdio.ai%2F&index=4&md5=a537a221c1f6b903ed43cf8fc24f8c1b)\n\nForward-Looking Statements\n\nCertain statements and information included in this press release constitute\n“forward-looking statements” within the meaning of the Private Securities\nLitigation Act of 1995. When used in this press release, the words or phrases\n“will”, “will likely result,” “expected to,” “will continue,”\n“anticipated,” “estimate,” “projected,” “intend,” “goal,”\nor similar expressions are intended to identify “forward-looking\nstatements” within the meaning of the Private Securities Litigation Reform\nAct of 1995. Such statements are subject to certain risks, known and unknown,\nand uncertainties, many of which are beyond the control of the Company. Such\nuncertainties and risks include but are not limited to, our ability to\nsuccessfully execute our growth strategy, changes in laws or regulations,\neconomic conditions, dependence on results are discussed in the Current Report\non Form 10-K for the period ended in December 31, 2025, under the heading\n“Risk Factors” in Part I, Item IA thereof, and other documents filed from\ntime to time with the Securities and Exchange Commission. Such factors could\nmaterially adversely affect the Company’s financial performance and could\ncause the Company’s actual results for future periods to differ materially\nfrom any opinions or statements expressed within this press release.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260624992562/en/\n(https://www.businesswire.com/news/home/20260624992562/en/)\n\nInvestors \n\nInvestor Relations\n\n855-226-9991\n\ninvestors@cdio.ai (mailto:investors@cdio.ai)\n\nMedia & Public Relations \n\nPublic Relations\n\n855-226-9991\n\npr@cdio.ai (mailto:pr@cdio.ai)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-06-24T12:35:00.157310322Z","server_sent_at_ms":1782304500157},"received_at":"2026-06-24T12:35:00.276Z","source_url":"https://www.businesswire.com/news/home/20260624992562/en/"},"analysis":{"id":"61407","press_release_id":"72034","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"partnership","narrative":"Cardio Diagnostics announced that Atlas Healthcare Physicians (AHP), a physician association in Southern California, will cover its Epi+Gen CHD and PrecisionCHD tests for members beginning in May 2026.\n\nThe agreement grants access to CDIO’s AI-powered blood tests across AHP’s network of primary care providers and specialists in Los Angeles and Orange County.\n\nCEO Meesha Dogan noted that the collaboration supports earlier risk identification and personalized care, reinforcing the company's strategy to expand access to precision cardiovascular medicine.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Regional network access expands test utilization footprint."},"keyFigures":null,"quotedText":"IPAs are uniquely positioned to drive better cardiovascular outcomes across their member populations and the right precision medicine tools can make a meaningful difference","namedEntities":{"people":[{"name":"Tam Doan","role":"COO of Atlas Healthcare Physicians"},{"name":"Meesha Dogan","role":"CEO of Cardio Diagnostics"}],"products":["Epi+Gen CHD™","PrecisionCHD™"],"companies":[{"name":"Cardio Diagnostics Holdings, Inc.","ticker":"CDIO"},{"name":"Atlas Healthcare Physicians","relationship":"partner"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Securing coverage from an independent physician association is a positive operational development for commercial adoption. However, the agreement is limited to a specific Southern California network (LA and Orange County) and no financial terms or contract values were disclosed."},"tickerRelevance":{"others":[],"primary":"CDIO"},"globalImportance":25,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"regional_partnership","sectorWeight":"health_care"}},"event_type":"partnership","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Cardio Diagnostics announced that Atlas Healthcare Physicians (AHP), a physician association in Southern California, will cover its Epi+Gen CHD and PrecisionCHD tests for members beginning in May 2026.\n\nThe agreement grants access to CDIO’s AI-powered blood tests across AHP’s network of primary care providers and specialists in Los Angeles and Orange County.\n\nCEO Meesha Dogan noted that the collaboration supports earlier risk identification and personalized care, reinforcing the company's strategy to expand access to precision cardiovascular medicine.","key_figures":null,"named_entities":{"people":[{"name":"Tam Doan","role":"COO of Atlas Healthcare Physicians"},{"name":"Meesha Dogan","role":"CEO of Cardio Diagnostics"}],"products":["Epi+Gen CHD™","PrecisionCHD™"],"companies":[{"name":"Cardio Diagnostics Holdings, Inc.","ticker":"CDIO"},{"name":"Atlas Healthcare Physicians","relationship":"partner"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-24T13:05:04.530Z","global_importance":25,"audience_relevance":20,"importance_components":{"tickerTier":"small-cap","eventGravity":"regional_partnership","sectorWeight":"health_care"}},"durationMs":125013,"modelName":"george-droid-qwen-72b"}}